| A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (NCT05061134) | AstraZeneca | 2022-08-11 |
| To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants. (NCT05065463) | AstraZeneca | 2022-08-10 |
| Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (NCT05398263) | AstraZeneca | 2022-08-09 |
| Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations (NCT05457257) | AstraZeneca | 2022-07-29 |
| CARE FOR ALL：an Evaluation of an Asthma QIP (NCT05440097) | AstraZeneca | 2022-07-29 |
| Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant (NCT05477108) | AstraZeneca | 2022-07-29 |
| Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study (NCT05697705) | AstraZeneca | 2022-07-22 |
| A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (NCT05364931) | AstraZeneca | 2022-07-14 |
| Tracking Treatment Pathways in Adult Patients With Hyperkalemia. (NCT05408039) | AstraZeneca | 2022-07-14 |
| A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC (NCT05246514) | AstraZeneca | 2022-07-13 |
| AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease (NCT05452304) | AstraZeneca | 2022-07-12 |
| A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) (NCT05460273) | AstraZeneca | 2022-07-11 |
| A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma (NCT04769869) | AstraZeneca | 2022-07-08 |
| Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population (NCT05966324) | AstraZeneca | 2022-07-05 |
| A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma (NCT05205161) | AstraZeneca | 2022-07-05 |
| Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. (NCT05267613) | AstraZeneca | 2022-07-01 |
| PORTHOS - PORTuguese Heart Failure Observational Study (NCT05434923) | AstraZeneca | 2022-06-30 |
| A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin (NCT05395117) | AstraZeneca | 2022-06-30 |
| A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab. (NCT05440656) | AstraZeneca | 2022-06-29 |
| A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ During Pregnancy (NCT05847140) | AstraZeneca | 2022-06-27 |
| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (NCT05417594) | AstraZeneca | 2022-06-24 |
| Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries (NCT05315323) | AstraZeneca | 2022-06-23 |
| Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers (NCT05438303) | AstraZeneca | 2022-06-13 |
| An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies (NCT05469919) | AstraZeneca | 2022-06-09 |
| A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours (NCT05397171) | AstraZeneca | 2022-06-07 |
| Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (NCT05367440) | AstraZeneca | 2022-06-02 |
| Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation) (NCT05454787) | AstraZeneca | 2022-06-02 |
| A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia (NCT05456867) | AstraZeneca | 2022-05-31 |
| PASS of Paediatric Patients Initiating Selumetinib (NCT05388370) | AstraZeneca | 2022-05-23 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects (NCT05384262) | AstraZeneca | 2022-05-18 |
| Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma (NCT05274815) | AstraZeneca | 2022-05-17 |
| Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST) (NCT05271526) | AstraZeneca | 2022-05-16 |
| Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI) (NCT05219630) | AstraZeneca | 2022-05-16 |
| A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) (NCT05374512) | AstraZeneca | 2022-05-16 |
| A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833 (NCT05364255) | AstraZeneca | 2022-05-10 |
| OPTIMISE-CKD Drug Utilization (NCT05932901) | AstraZeneca | 2022-05-04 |
| Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States (NCT05329194) | AstraZeneca | 2022-04-29 |
| A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease (NCT05432167) | AstraZeneca | 2022-04-29 |
| VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA (NCT05135455) | AstraZeneca | 2022-04-21 |
| Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice (NCT05250011) | AstraZeneca | 2022-04-19 |
| Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab (NCT05303532) | AstraZeneca | 2022-04-19 |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NCT05061550) | AstraZeneca | 2022-04-14 |
| Forxiga CKD Japan Post-Marketing Surveillance (PMS) (NCT05306210) | AstraZeneca | 2022-04-12 |
| A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib) (NCT05419401) | AstraZeneca | 2022-04-11 |
| Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 (NCT05459688) | AstraZeneca | 2022-04-06 |
| A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry (NCT05351047) | AstraZeneca | 2022-04-04 |
| Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (NCT05301842) | AstraZeneca | 2022-03-28 |
| A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects (NCT05294458) | AstraZeneca | 2022-03-28 |
| Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT05348577) | AstraZeneca | 2022-03-25 |
| Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab (NCT05339100) | AstraZeneca | 2022-03-22 |
| A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China (NCT05271266) | AstraZeneca | 2022-03-22 |
| Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components (NCT05266404) | AstraZeneca | 2022-03-21 |
| AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics (NCT05281601) | AstraZeneca | 2022-03-21 |
| Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT05216835) | AstraZeneca | 2022-03-18 |
| REported Outcomes in COPD With Trixeo in Real worlD in Germany (NCT05311306) | AstraZeneca | 2022-03-15 |
| FASENRA Regulatory Postmarketing Surveillance in Korea (NCT05091333) | AstraZeneca | 2022-03-11 |
| Dapagliflozin Post Marketing Surveillance in HF and CKD (NCT05134701) | AstraZeneca | 2022-03-10 |
| Association of the Risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 Vaccines (NCT05252442) | AstraZeneca | 2022-03-01 |
| Epidemiology of Thrombotic Thrombocytopenia Syndrome in Integrated Health-care Database in England (NCT05222750) | AstraZeneca | 2022-03-01 |
| Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia: (NCT04836975) | AstraZeneca | 2022-02-28 |
| Chinese Multiple Dose Escalation (MDE) High Dose Study (NCT05437848) | AstraZeneca | 2022-02-25 |
| Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). (NCT05219162) | AstraZeneca | 2022-02-25 |
| Prevalence and Clinicopathologic Features of Different HER2 Level in Chinese Breast Cancer Patients (NCT05203458) | AstraZeneca | 2022-02-24 |
| A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (NCT05120349) | AstraZeneca | 2022-02-21 |
| A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole (NCT05236543) | AstraZeneca | 2022-02-18 |
| A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (NCT05211895) | AstraZeneca | 2022-02-18 |
| EU Secondary Data Post-Authorisation Safety Study of AZD1222 (NCT05126992) | AstraZeneca | 2022-02-18 |
| Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis (NCT05138133) | AstraZeneca | 2022-02-15 |
| A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NCT05221840) | AstraZeneca | 2022-02-07 |
| Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. (NCT05158387) | AstraZeneca | 2022-02-07 |
| LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study (NCT05282017) | AstraZeneca | 2022-02-01 |
| OREIOS International Study (NCT05239507) | AstraZeneca | 2022-02-01 |
| A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults (NCT05057897) | AstraZeneca | 2022-01-31 |
| Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma (NCT05251259) | AstraZeneca | 2022-01-27 |
| A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers (NCT04949438) | AstraZeneca | 2022-01-21 |
| Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN (NCT05309668) | AstraZeneca | 2022-01-21 |
| Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC (NCT05215951) | AstraZeneca | 2022-01-19 |
| Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) (NCT05251909) | AstraZeneca | 2022-01-18 |
| A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS) (NCT05202262) | AstraZeneca | 2022-01-12 |
| Zoladex® 10.8 BC RWS (NCT05184257) | AstraZeneca | 2022-01-06 |
| Comparative Study of the Efficacy of Biologics vs Usual Treatment on OCS Reduction for Severe Asthma Patients Using Health Insurance Claim Database (NCT05136547) | AstraZeneca | 2022-01-06 |
| Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (NCT05166889) | AstraZeneca | 2022-01-03 |
| DOuBLED - Doubling Outcomes by Lung Cancer Early Diagnosis (NCT05091437) | AstraZeneca | 2021-12-30 |
| QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance (NCT05160974) | AstraZeneca | 2021-12-30 |
| SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS) (NCT05141201) | AstraZeneca | 2021-12-21 |
| A Safety Study of AZD4041 in Healthy Participants (NCT05233085) | AstraZeneca | 2021-12-17 |
| A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists (NCT05110976) | AstraZeneca | 2021-12-16 |
| AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL (NCT05140382) | AstraZeneca | 2021-12-15 |
| Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours (NCT04999969) | AstraZeneca | 2021-12-10 |
| The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap Patients (NCT04905420) | AstraZeneca | 2021-12-08 |
| A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults (NCT05184062) | AstraZeneca | 2021-12-03 |
| Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC (NCT04416633) | AstraZeneca | 2021-11-30 |
| Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels (NCT05184998) | AstraZeneca | 2021-11-30 |
| Real-world Dapagliflozin Experience in Patients With Heart Failure in United Kingdom. (NCT05188144) | AstraZeneca | 2021-11-29 |
| Exacerbations and Their Outcomes International (EXACOS International) (NCT04928417) | AstraZeneca | 2021-11-26 |
| Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants (NCT05107336) | AstraZeneca | 2021-11-25 |
| Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China (NCT05110261) | AstraZeneca | 2021-11-24 |
| Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure (NCT04890548) | AstraZeneca | 2021-11-23 |
| RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps. (NCT05180357) | AstraZeneca | 2021-11-23 |
| FAsenra Safety Trial in India (NCT05384938) | AstraZeneca | 2021-11-19 |